Design Therapeutics CEO reports vesting of performance stock options

Design Therapeutics disclosed that its President, CEO and Chairperson, who also serves as a director, holds a stock option to purchase 525,000 shares of common stock at an exercise price of $2.48 per share, originally granted on September 1, 2023.

Rhea-AI Filing Summary

Design Therapeutics disclosed that its President, CEO and Chairperson, who also serves as a director, holds a stock option to purchase 525,000 shares of common stock at an exercise price of $2.48 per share, originally granted on September 1, 2023.

The option was subject to both time-based vesting and a specific performance condition. On December 9, 2025, the board determined that the performance condition had been met, causing 295,312 of these option shares to vest. The remaining unvested portion is scheduled to vest in equal monthly installments through August 25, 2027, as long as the executive continues to provide service to the company.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Shah Pratik

Role President, CEO and Chairperson

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	525,000	$0.00	$0.00
Grant/Award	Stock option (right to buy)	525,000	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 1,050,000 shares (Direct)

Footnotes (1)

1. F1. On September 1, 2023, the Reporting Person was granted an option to purchase 525,000 shares of common stock. 25% of the shares subject to the option would vest on August 25, 2024, and thereafter the balance would vest in equal monthly installments over the following 36 months, provided that, as an additional condition, no shares under the option would vest until the Issuer achieved a specific performance condition. On December 9, 2025, the Issuer's Board of Directors deemed that the performance condition had been met, resulting in vesting of the option as to 295,312 shares. The remainder of the unvested shares subject to the option shall vest monthly through August 25, 2027 subject to the continuous service of the Reporting Person through each such date.

FAQ

What insider equity award did Design Therapeutics (DSGN) disclose?

The company reported that its President, CEO and Chairperson holds a stock option to purchase 525,000 shares of common stock at an exercise price of $2.48 per share.

When was the Design Therapeutics (DSGN) stock option originally granted?

The option to purchase 525,000 shares of Design Therapeutics common stock was originally granted on September 1, 2023.

What performance condition affected vesting of the DSGN stock option?

The option’s vesting depended on a specific performance condition set by the company. On December 9, 2025, the board determined that this condition had been met, triggering partial vesting.

How many Design Therapeutics (DSGN) option shares vested when the performance condition was met?

When the board determined the performance condition had been satisfied on December 9, 2025, the option vested as to 295,312 shares of common stock.

What is the remaining vesting schedule for the DSGN stock option?

The remaining unvested shares under the 525,000-share option are scheduled to vest in equal monthly installments through August 25, 2027, subject to the reporting person’s continuous service.

What roles does the reporting person hold at Design Therapeutics (DSGN)?

The reporting person is identified as a director and an officer of Design Therapeutics, serving as President, CEO and Chairperson.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/11/2025 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shah Pratik

(Last) (First) (Middle)

C/O DESIGN THERAPEUTICS, INC.

6005 HIDDEN VALLEY ROAD, SUITE 110

(Street)

CARLSBAD CA 92011

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Design Therapeutics, Inc. [ DSGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, CEO and Chairperson

3. Date of Earliest Transaction (Month/Day/Year)
12/09/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$2.48	12/09/2025		A		525,000		(1)	(1)	Common Stock	525,000	$0	525,000	D
Stock option (right to buy)	$2.48	12/09/2025		A		525,000		(1)	(1)	Common Stock	525,000	$0	525,000	D

Explanation of Responses:

1. On September 1, 2023, the Reporting Person was granted an option to purchase 525,000 shares of common stock. 25% of the shares subject to the option would vest on August 25, 2024, and thereafter the balance would vest in equal monthly installments over the following 36 months, provided that, as an additional condition, no shares under the option would vest until the Issuer achieved a specific performance condition. On December 9, 2025, the Issuer's Board of Directors deemed that the performance condition had been met, resulting in vesting of the option as to 295,312 shares. The remainder of the unvested shares subject to the option shall vest monthly through August 25, 2027 subject to the continuous service of the Reporting Person through each such date.

	/s/ Mustapha Parekh, Attorney-in-Fact	12/11/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.